ESD plus chemoradiotherapy for early esophageal cancer
Part of Cancer, Digestive system clinical trials.
This study tests whether combining radiation and chemotherapy after endoscopic removal of early-stage esophageal cancer can effectively treat the cancer without needing surgery. It may be an option for people whose cancer was removed with ESD but who want to avoid additional surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have esophageal cancer that was removed by an endoscopic procedure called ESD
- The cancer was found to be at an early stage (pT1a-MM or pT1b)
- You are able to safely receive chemotherapy and radiation therapy
- You have chosen not to have surgery after the ESD
- You do not have severe heart, lung, brain, or kidney disease
- You have not had another cancer before or any prior chemotherapy or radiation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding radiation therapy after endoscopic surgery (ESD) helps people with early-stage esophageal cancer that had certain high-risk features, like deeper invasion or positive margins. It aims to improve outcomes for those who didn't get a complete cure with surgery alone.
This study compares two treatment approaches for certain locally advanced esophageal cancers: chemoradiation (chemo plus radiation) versus esophagus surgery. It may help find which option works better to control the cancer and improve outcomes.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial tests whether adding immunotherapy to standard chemoradiation (chemotherapy plus radiation) can help preserve the esophagus and avoid surgery in people with resectable esophageal cancer. It aims to see if this combination is safer and more effective than current treatment.
This trial tests whether giving chemotherapy combined with immunotherapy before surgery works better than the standard chemoradiation for esophageal cancer that can be removed. It may help reduce tumor size and improve outcomes.
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
Hear when a new Esophagus Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.